Cirrhosis in Medical Technology

Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis

... predisposes patients to develop primary biliary cirrhosis , a disease that mainly affects women and slowly destroys their livers. Primary biliary cirrhosis has no known cause. The finding, significant ... Currently, treatments for primary biliary cirrhosis can slow progression of the disease, which ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... (IR) Therapy: Final Results of the EPIC3 cirrhosis Maintenance Trial(1) The large EPIC3 ... people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for ... (IR) Therapy: Final Results of the EPIC3 cirrhosis Maintenance Trial. Oral presentation at: 44th ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV ... liver disease and histological evidence of cirrhosis (Child-Pugh class A). Alpha interferons, ... Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV ... liver disease and histological evidence of cirrhosis (Child-Pugh class A). Alpha interferons, ... Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and ...

Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin

... were higher for extended treatment. Patients with cirrhosis had a somewhat higher incidence of adverse ... liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV ... Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

... trial in which 2,293 adult patients with moderate-to-severe fibrosis or cirrhosis who failed previous treatment with combination alpha interferon/ribavirin ... 5 million people in the United States alone. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the ...

Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis

... can be reversed if patients stop drinking, the disease can progress to cirrhosis and liver failure." In this placebo-controlled clinical trial, ... the majority of people with alcoholic hepatitis eventually develop cirrhosis and die, says Dr. Shah. Mayo Clinic's Division of ...

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients

... in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically ... Registry at 1-800-593-2214. Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha ...

Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests

... can cause chronic liver disease and puts people at high risk of death from cirrhosis of the liver and liver cancer. Approximately 2 billion people worldwide ... chronically infected during childhood later die from liver cancer or cirrhosis (scarring of the liver). Hepatitis B virus is 50 to 100 times more ...

PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C

... in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically ... Registry at 1-800-593-2214. Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting

... the EPIC3 program. Poynard, T. et. al. Impact of viral load and cirrhosis on treatment outcome in HCV genotype 3-infected patients: results of the ... Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the ...

Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil

... in 70% of survivors The most common cause of portal hypertension is cirrhosis of the liver due to alcohol abuse or hepatitis. cirrhosis from chronic liver disease ranks among the top 15 causes of death ...

Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART

... with cirrhosis. Data from 23 patients with chronic hepatitis B and cirrhosis were collected. Among them, 5 patients were diagnosed with decompensated liver cirrhosis or hepatocellular carcinoma (HCC). For patients who received clevudine for ...

Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks

... in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically ... Registry at 1-800-593-2214. Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha ...

New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families

... Study shows one in five sisters of a primary biliary cirrhosis patient has the biomarker of the disease ROCHESTER, Minn., Sept. 10 ... (i.e., parents, siblings, children) of patients with primary biliary cirrhosis (PBC) are more likely to have the biomarker of the disease in their blood. ...

ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases

... other life threatening diseases. NAFLD is known to progress to more advanced liver diseases such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and liver cancer. Nanoveson(TM) is a novel approach to treating and diagnosing liver diseases and comorbid diseases utilizing the principles of ...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... of the liver, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of ...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

... affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe. About PEGINTRON PEGINTRON is indicated ...

MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer

... parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients. Primary liver cancer is rarely discovered early, and often does not respond to current treatment. For ...

Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)

... form of liver disease that accounts for approximately 10% of newly diagnosed cases of chronic liver disease, is one of the leading causes of cirrhosis in the U.S. NASH patients are currently limited to managing their disease through weight control, diet and exercise. (Logo: ....

ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients

... of the liver, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... occurred in patients greater than 55 years of age. Most reports of hepatic failure involved patients with significant comorbidities, including liver cirrhosis and multi-organ failure. Monitor liver function tests monthly during Exjade treatment and consider dose modifications or interruption for severe or ...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe. About PEGINTRON In the United ...

Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008

... people in the United States are infected with chronic HCV and 19,000 people are newly infected each year.(4) Chronic infection with HCV can lead to cirrhosis and liver cancer, and is the most common cause of liver transplant in the United States.(4,5) About Tibotec BVBA Tibotec BVBA is a global ...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe. About PEGINTRON In the United States, ...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

... of the liver, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of ...

Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)

... form of liver disease that accounts for approximately 10% of newly diagnosed cases of chronic liver disease, is one of the leading causes of cirrhosis in the U.S. (Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO ) Under a previously announced collaboration agreement between ...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

... of the liver, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of ...

Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program

... vaccine trials, to a level not yet seen for other known adjuvants. About Hepatitis C HCV is a major cause of chronic liver disease, including cirrhosis and liver cancer. According to the World Health Organization (WHO), approximately 170 million people worldwide are chronic HCV carriers (3% of the ...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

... affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe. About PEGINTRON In the United States, ...

Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease

... weight. Though most people with NASH feel healthy and show no outward signs of liver disease, NASH causes liver scarring and potentially leads to cirrhosis and liver failure. In more severe cases, the progressive nature of NASH may require liver transplantation in affected patients. Ranjan Dohil, ...

Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease

... attention to two significant safety concerns: Potential for serious liver injury (including rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) -- Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. High ...

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

... people worldwide. HCV causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately, liver failure. cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of ...

Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension

... PAH can occur with no known underlying cause, or it can occur secondary to diseases such as connective tissue disease, congenital heart defects, cirrhosis of the liver and HIV infection. About Ergonex Pharma Ergonex Pharma is a pharmaceutical company focussed on developing and commercialising ...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

... affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe. About PEGINTRON In the United States, ...

Important Progress Toward Control of Hepatitis B and C

... has to be restarted, and continued for life. Currently, it is only feasible to treat those patients with severe progressive HBV, to prevent eventual cirrhosis and hepatocellular carcinoma. It is impractical to treat someone with HBV who is simply a healthy carrier, both because of the cost and because ...

NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease

... of developing liver cirrhosis, and its complications, including hepatocellular carcinoma, the most frequent primary tumour of the liver. NASH-related cirrhosis is an increasingly occurring indication for liver transplantation. In turn, the metabolic syndrome is a combination of risk factors, including high ...

FDA Grants Priority Review for PROMACTA(R) (eltrombopag)

... REVOLADE(R). The compound is also being studied for long-term treatment of chronic ITP, as well as thrombocytopenia associated with Hepatitis C Virus cirrhosis and chemotherapy induced thrombocytopenia. About ITP Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate ...

Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)

... with a reasonable number of patients required for the trial." "Hepatic encephalopathy ("HE") represents one of the most frequent complications of cirrhosis mandating hospitalization and a two-stage improvement of HE has significant clinical benefits to patients," noted Dr. John Vierling, M.D. FACP ...

Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay

... common serious liver infection in the world and is transmitted through contact with blood and body fluids. HBV infection can lead to liver failure, cirrhosis or cancer. According to the World Health Organization, more than 350 million people worldwide are chronically infected with HBV. More than one ...